If Novo Nordisk is to fulfil the potential of its anti-obesity drug Saxenda, it needs more doctors to have a new understanding of how obesity really works. And to prescribe. Again and again.
Novo Nordisk wants to change the way Australians think about obesity. And if it is successful, it could make a killing.
INQ, a team of a dozen reporters and editors — and our biggest single investment in journalism — will launch in two weeks.